MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference

Rhea-AI Summary

Marianna, Ga. - MiMedx Group, with the stock symbol MDXG, has announced its participation in the Raymond James 2021 Human Health Innovation Conference on June 23, 2021, at 11:20 AM ET. The presentation will feature CEO Timothy R. Wright, CFO Peter M. Carlson, and EVP Robert B. Stein, M.D., Ph.D. Interested parties can access the live webcast via the company’s website or through the conference link. MiMedx specializes in regenerative medicine using amniotic tissue and has shipped over two million allografts, focusing on treating chronic wounds and degenerative conditions.

MARIETTA, Ga, June 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will present at the Raymond James 2021 Human Health Innovation Conference on Wednesday, June 23, 2021 at 11:20 AM Eastern Time.

Date: Wednesday, June 23, 2021
Time: 11:20 AM ET
Webcast: https://kvgo.com/rj-health/mimedx-group-inc-june-2021

A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the link above. A replay will be available on the Company’s website following the event.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION^® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com. 

Contacts:
Investors
Jack Howarth
404-360-5681
investorrelations@MIMEDX.com

FAQ

When is the MiMedx Group presentation at the Raymond James 2021 Human Health Innovation Conference?

The MiMedx Group presentation is scheduled for June 23, 2021, at 11:20 AM Eastern Time.

Who will represent MiMedx Group at the conference?

Timothy R. Wright, Peter M. Carlson, and Robert B. Stein, M.D., Ph.D., will represent MiMedx Group at the conference.

How can I access the MiMedx Group conference presentation?

You can access the MiMedx Group conference presentation via a live webcast on their website or through the provided conference link.

What is MiMedx Group known for?

MiMedx Group is known for its use of amniotic tissue in regenerative medicine, focusing on healing chronic wounds and easing degenerative conditions.

How many allografts has MiMedx Group supplied?

MiMedx Group has supplied over two million allografts to date.